(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €33.62 | 3.99% | 8.64% |
| CONTEXTVISION (CONTX.OL) | kr6.16 | 3.46% | 61.1% |
| MEDISTIM (MEDI.OL) | kr174.00 | 2.56% | 27.12% |
| ESSILORLUXOTTICA (EL.PA) | €209.70 | 1.94% | 6.3% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
3.99% Forward Dividend Yield and 8.64% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing €12.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.64%.
Volume
Today’s last reported volume for BOIRON is 1545 which is 88.44% below its average volume of 13371.
Yearly Top and Bottom Value
BOIRON’s stock is valued at €33.62 at 22:30 EST, way under its 52-week high of €56.50 and higher than its 52-week low of €32.48.
Moving Average
BOIRON’s worth is below its 50-day moving average of €34.69 and way below its 200-day moving average of €43.03.
More news about BOIRON.
2. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary uses. Its products include Rivent that offers image enhancement and visualization solutions for ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, a 2D image enhancement product for handheld units; and Rivent 3D, an image enhancement solution for 3D ultrasound. The company also provides Altumira/Altumira Plus, an artificial intelligence-powered image enhancement product for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.42.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 14.67. Meaning, the purchaser of the share is investing kr14.67 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CONTEXTVISION’s EBITDA is 49.39.
Volatility
CONTEXTVISION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.62%, a negative 0.74%, and a positive 2.37%.
CONTEXTVISION’s highest amplitude of average volatility was 1.62% (last week), 1.87% (last month), and 2.37% (last quarter).
Volume
Today’s last reported volume for CONTEXTVISION is 1534 which is 96.98% below its average volume of 50843.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.
More news about CONTEXTVISION.
3. MEDISTIM (MEDI.OL)
2.56% Forward Dividend Yield and 27.12% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. It operates through Sale of Own Products; and Sale of 3. Party Products segments. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; MiraQ Ultimate, which uses flow measurement and ultrasound imaging probes to provide a complete assessment; and imaging probes for intraoperative use. It also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical devices. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.67.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 30.69. Meaning, the purchaser of the share is investing kr30.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.12%.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was 1.03%, 0.26%, and 1.83%.
MEDISTIM’s highest amplitude of average volatility was 2.92% (last week), 2.17% (last month), and 1.83% (last quarter).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2024, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.56%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be oversold (<=20).
More news about MEDISTIM.
4. ESSILORLUXOTTICA (EL.PA)
1.94% Forward Dividend Yield and 6.3% Return On Equity
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.08.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 41.28. Meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.3%.
More news about ESSILORLUXOTTICA.
